TNFRSF8 and systemic mastocytosis: Indeed, phase I and II trials[18] demonstrated that the monoclonal antibody brentuximab vedotin yielded meaningful control of Hodgkin Lymphoma, peripheral T-cell Lymphoma, cutaneous T-cell Lymphoma, and even in cases of SM.[10] These findings illustrate that CD30 is a potential target for the treatment of mastocytosis.